These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25229226)

  • 1. First report on ototoxicity of meglumine antimoniate.
    Valete-Rosalino CM; Araujo-Melo MH; Bezerra DC; Barcelos RO; Melo-Ferreira Vd; Torraca TS; Martins AC; Moreira JS; Vargas MC; Braga FP; Salgueiro Mde M; Saheki MN; Schubach AO
    Rev Inst Med Trop Sao Paulo; 2014; 56(5):439-42. PubMed ID: 25229226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis.
    Duarte CCJ; Torraca TSS; Bezerra DO; Oliveira RB; Leite NKS; de Oliveira RVC; Araújo-Melo MH; Pimentel MIF; Costa ADD; Vasconcellos ÉCF; Lyra MR; Soares ECDA; Paes LRDNB; Salgueiro MM; Schubach AO; Valete CM
    PLoS One; 2024; 19(2):e0296728. PubMed ID: 38354178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients.
    Oliveira Bezerra DC; Oliveira de Barcelos R; Carvalho de Castro E; Jardim Duarte CC; de Vasconcellos Carvalhaes Oliveira R; Salgado de Sousa Torraca T; de Araújo-Melo MH; Pereira Bom Braga F; Ramos Ferreira Terceiro B; do Nascimento Brahim Paes LR; de Oliveira Schubach A; Valete-Rosalino CM
    PLoS One; 2017; 12(1):e0168492. PubMed ID: 28045920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
    Rodrigues ML; Costa RS; Souza CS; Foss NT; Roselino AM
    Rev Inst Med Trop Sao Paulo; 1999; 41(1):33-7. PubMed ID: 10436668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
    López L; Robayo M; Vargas M; Vélez ID
    Trials; 2012 May; 13():58. PubMed ID: 22594858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.
    Ferreira e Vasconcellos Ede C; Pimentel MI; Valete-Rosalino CM; Madeira Mde F; Schubach Ade O
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):361-2. PubMed ID: 25076440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
    Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
    Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
    Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Report of a case].
    Cucé LC; Belda Júnior W; Dias MC
    Rev Inst Med Trop Sao Paulo; 1990; 32(4):249-51. PubMed ID: 2101518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Meglumine antimoniate].
    Silva JB
    Rev Soc Bras Med Trop; 2001; 34(1):103-5. PubMed ID: 11340506
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis.
    Rahman A; Tahir M; Naveed T; Abdullah M; Qayyum N; Malik DH; Amin B
    J Coll Physicians Surg Pak; 2023 Dec; 33(12):1367-1371. PubMed ID: 38062590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug hypersensitivity syndrome induced by meglumine antimoniate.
    Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
    Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
    Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
    J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
    Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
    J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Symptomatic hypokalemia caused by meglumine antimoniate].
    Bouvresse S; Matichard E; Mahé E; Marinho E; Soria A; Devillière M; Descamps V; Crickx B
    Ann Dermatol Venereol; 2007 Apr; 134(4 Pt 1):387-8. PubMed ID: 17483764
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case of urticaria during pentavalent antimony use in a patient with mucous leishmaniasis].
    Oliveira MR; Marsden PD
    Rev Soc Bras Med Trop; 1995; 28(3):287. PubMed ID: 7480927
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute pancreatitis caused by meglumine antimoniate given for the treatment of visceral leishmaniasis.
    Lambertucci JR; França BM; Queiroz Ede M
    Rev Soc Bras Med Trop; 2004; 37(1):74-5. PubMed ID: 15042193
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.
    Kuyucu N; Kara C; Bakirtaç A; Teziç T
    Pediatr Infect Dis J; 2001 Apr; 20(4):455-7. PubMed ID: 11332679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
    Castro C; Sampaio RN; Marsden PD
    Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
    [No Abstract]   [Full Text] [Related]  

  • 20. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.